Biofrontera | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 12 M

Revenue: As of FY2026 Q2, the actual value is USD 12 M, beating the estimate of USD 9.5 M.

EPS: As of FY2026 Q2, the actual value is USD -0.05, beating the estimate of USD -0.105.

EBIT: As of FY2026 Q2, the actual value is USD -455 K.

Second Quarter 2026 Financial Highlights

Net Product Revenue

Biofrontera Inc. reported net product revenue of $12.0 million, marking a 32.9% increase from $9.0 million in the prior-year period.

Gross Margin

The company achieved a gross margin of 80%, an improvement of approximately 920 basis points compared to 71% in the prior-year period.

Net Loss

Net loss was - $0.6 million, a significant reduction from - $5.3 million in the prior-year period.

Adjusted EBITDA

Adjusted EBITDA improved to - $0.2 million, compared to - $5.1 million in the prior-year period, representing an improvement of approximately $5.0 million.

Cost of Revenues

Cost of revenues was $2.4 million, down from $2.6 million in the prior-year period.

Gross Profit

Gross profit stood at $9.6 million, up from $6.4 million in the second quarter of 2025.

Selling, General and Administrative Expenses

These expenses decreased by $0.9 million to $9.7 million from $10.6 million in the prior-year quarter.

Research and Development Expenses

Research and development expenses were $0.4 million, compared to $0.9 million in the prior-year quarter.

Loss from Operations

Loss from operations was - $0.524 million, a notable improvement from - $5.079 million in the prior-year period.

First Half 2026 Financial Highlights

Net Product Revenue

Net product revenue for the first six months was $22.1 million, an increase of 25.4% from $17.6 million in the prior-year period.

Gross Margin

Gross margin was 80%, up from 67% in the prior-year period.

Net Loss

Net loss was - $5.4 million, an improvement from - $9.5 million in the prior-year period.

Adjusted EBITDA

Adjusted EBITDA was - $3.7 million, compared to - $9.5 million in the prior-year period.

Cash Used in Operating Activities

Cash used in operating activities was $1.7 million, a 76% reduction from $7.2 million in the prior-year period.

Cost of Revenues

Cost of revenues was $4.5 million, compared to $5.9 million in the prior-year period.

Gross Profit

Gross profit was $17.6 million, compared to $11.7 million in the prior-year period.

Selling, General and Administrative Expenses

These expenses increased to $20.7 million from $19.3 million in the prior-year period.

Research and Development Expenses

Research and development expenses were $1.3 million, compared to $2.1 million in the prior-year period.

Loss from Operations

Loss from operations was - $4.844 million, an improvement from - $9.629 million in the prior-year period.

Balance Sheet and Cash Flow (as of June 30, 2026)

Cash and Cash Equivalents

Cash and cash equivalents stood at $4.7 million, down from $6.4 million as of December 31, 2025.

Total Liabilities

Total liabilities remained essentially unchanged at $18.1 million compared to December 31, 2025.

Outstanding Indebtedness

The company’s outstanding indebtedness consisted of $4.6 million in convertible notes, net, maturing in November 2027.

Total Stockholders’ Equity

Total stockholders’ equity was $6.0 million, compared to $10.5 million at December 31, 2025.

Outlook / Guidance

Biofrontera Inc. anticipates continued strong underlying demand for Ameluz® and expects to launch Ameluz® for superficial basal cell carcinoma (sBCC) in Q1 2027. The company is progressing towards achieving cash flow breakeven in 2026. This goal is expected to be unaffected by the ITC order impacting RhodoLED XL lamps.